

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





Product Data Sheet

Nelotanserin

Cat. No.: HY-10559

CAS No.: 839713-36-9

Molecular Formula: C₁₈ H₁₅ BrF₂ N₄ O₂

Molecular Weight: 437.24

Target: 5-HT Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: $\geq 32 \text{ mg/mL} (73.19 \text{ mM})$

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.2871 mL	11.4354 mL	22.8707 mL
	5 mM	0.4574 mL	2.2871 mL	4.5741 mL
	10 mM	0.2287 mL	1.1435 mL	2.2871 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

DescriptionNelotanserin is a potent 5-HT_{2A} inverse agonist, a moderately potent 5-HT_{2C} partial inverse agonist and a weak 5-HT_{2B} inverse agonist, with IC₅₀s of 1.7, 79, 791 nM in IP accumulation assays, respectively.

inverse agoinst, with 16503 of 1.1, 7.3, 7.31 film in accumulation assays, respectively

In Vitro

Results from IP accumulation assays suggest that Nelotanserin is a potent 5-HT $_{2A}$ full inverse agonist (IC $_{50}$ =1.7 nM), a moderately potent 5-HT $_{2C}$ partial inverse agonist (IC $_{50}$ =79 nM) (maximal response was 62% of the response obtained for the reference inverse agonist clozapine), and a weak 5-HT $_{2B}$ inverse agonist (IC $_{50}$ =791 nM). Nelotanserin displays high affinity for recombinant human 5-HT $_{2A}$ receptors (K $_{i}$ =0.35 nM), moderate affinity for human 5-HT $_{2C}$ receptors (K $_{i}$ =100 nM), and low affinity for human 5-HT $_{2B}$ receptors (2000 nM) stably expressed in HEK293 cells. The results suggest that Nelotanserin has a 262-fold higher affinity for human 5-HT $_{2A}$ than 5-HT $_{2C}$ receptors and a 6610-fold higher affinity for human 5-HT $_{2A}$ than 5-HT $_{2B}$ receptors^[1].

 ${\tt MCE}\ has\ not\ independently\ confirmed\ the\ accuracy\ of\ these\ methods.\ They\ are\ for\ reference\ only.$

In Vivo

Each compound is tested in a minimum of five rats by oral gavage with administration occurring in the middle of the inactive period, 6 h after light onset. The delta power during non-REM sleep (NREMS) is significantly different between all the analogues tested and the vehicle control. Nelotanserin (Compound 39) produces significant increases in delta power that persist for the first 4 h following dosing. Significant differences are found, however, in NREMS bout length. Nelotanserin significantly increases NREMS bout length during the first hour following dosing, and 3 does so during the second hour. In conjunction with this increased NREM bout duration, the number of NREM bouts decrease during the first hour for Nelotanserin (p<0.01) as well as for compound 15 (p<0.05)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

• ACS Chem Neurosci. 2019 Nov 20;10(11):4476-4491.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Al-Shamma HA et al. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther. 2010 Jan;332(1):281-90.

[2]. Teegarden BR et al. Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia. J Med Chem. 2010 Mar 11;53(5):1923-36.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA